4-Thiazolecarboxylic Acid, 2-Chloro-, Methyl Ester

Substituting the carboxylic acid terminus of a lead pharmacophore with a 2-chlorothiazole-4-carboxylate methyl ester bioisostere has enabled access to a distinct IP space in several anti-inflammatory programmes. In a typical kilogram-scale campaign, the methyl ester (1.0 eq., >99.5% by HPLC, single impurity threshold <0.10% per ICH Q3A) is dissolved in anhydrous tetrahydrofuran (8.0 L per kg of ester) and treated with lithium hydroxide monohydrate (1.05 eq.) in deionized water (2.0 L) at 0–5 °C in a 50-L glass-lined reactor fitted with a retreat-curve impeller. The saponification is monitored by inline Raman spectroscopy tracking the disappearance of the methyl ester C=O stretch at 1735 cm⁻¹; conversion exceeds 99% within 4 h. After acidification with 6 N hydrochloric acid at <5 °C, the free acid is filtered and dried at 40 °C in vacuo. The 2-chloro acid is then activated with EDC hydrochloride (1.2 eq.) and HOBt hydrate (1.2 eq.) in dichloromethane, followed by addition of a substituted benzylamine (1.0 eq.) at 25 °C over 30 min. The amide product is isolated by flash chromatography on 200–300 mesh silica gel using 30% ethyl acetate in heptane, delivering a 78–85% overall two-step yield with 97.8% purity. Terminal pharmaceutical candidates derived from this intermediate include fatty acid amide hydrolase (FAAH) inhibitors, where the 2-chloro handle permits late-stage diversification. From a regulatory standpoint, this chemical is introduced as a GMP starting material under ICH Q11, with residual solvent limits validated per USP <467>. The batch records document that the crude amide holds at −20 °C for ≤72 h before purification to prevent hydrolysis by ambient moisture. Published data for this specific configuration is limited; however, internal process robustness studies confirm acceptable impurity profiles across five consecutive manufactured batches.

How Can the 2-Chloro Substituent Be Exploited for Regioselective C–H Functionalisation in Drug Discovery?

Directed ortho‑metalation of 2‑chloro‑4‑thiazolecarboxylic acid methyl ester using freshly prepared lithium diisopropylamide (1.2 eq. in THF/heptane/ethylbenzene) at −78 °C under argon permits exclusive deprotonation at the 5‑position of the thiazole ring. The resulting lithiated species is quenched with a pre‑chilled solution of iodine (1.5 eq. in THF, added via cannula over 20 min) to generate the 2‑chloro‑5‑iodo intermediate in 89–93% in‑situ yield. Tight temperature control (±3 °C) during deprotonation is critical because a competing halogen‑lithium exchange on the 2‑position occurs at temperatures above −65 °C, leading to ring‑opening byproducts that are detectable as an off‑gas evolution measured by an MFC‑calibrated gas flowmeter in the reactor headspace. The process is executed in a 20‑L jacketed cylindrical vessel equipped with a four‑blade pitched turbine and an in‑line ReactIR probe set to collect spectra every 5 seconds; a drop in the lithiated species absorbance at 1480 cm⁻¹ confirms complete consumption of LDA before the iodine quench commences. After quenching, the batch is warmed to −10 °C and quenched with aqueous ammonium chloride (10% w/w). The organic phase is concentrated and the 5‑iodo ester is purified by vacuum distillation (125–128 °C at 0.5 mbar) to afford >99.0% purity. The iodinated building block subsequently undergoes Suzuki‑Miyaura coupling with aryl boronic acids using Pd(OAc)₂/SPhos (1.5 mol %) and K₃PO₄ in toluene/water at 80 °C, furnishing 2‑chloro‑5‑aryl‑4‑carboxylate methyl esters. These intermediates serve as kinase inhibitor scaffolds where the chlorine at C‑2 is ultimately displaced with primary amines under Buchwald‑Hartwig conditions. Safety assessment follows the practice outlined in the European Federation of Chemical Engineering Guidelines for limiting thermal runaway; differential scanning calorimetry gives an onset temperature of 112 °C for the dechlorination side reaction, well outside the operational window.

Process safety evaluations of the methyl ester’s conversion to the corresponding acyl chloride identified a significant exotherm (ΔT_ad = 68 K) when thionyl chloride was added at 25 °C, mandating controlled dosing at 0–5 °C in a toluene diluent. In a dedicated 100‑L Hastelloy C‑276 reactor, 2‑chloro‑4‑thiazolecarboxylic acid methyl ester (1.0 eq., 8.5 kg) is dissolved in dry toluene (42 L). A solution of thionyl chloride (1.8 eq.) and DMF (0.05 eq.) is metered below the liquid surface at a rate that keeps the internal temperature below 5 °C, with total addition taking 5–6 h. In‑process monitoring by aliquot quenching into excess morpholine followed by GC‑FID reveals 96% conversion to the acyl chloride after 2 h of post‑addition stirring at 20 °C. The resulting solution is employed directly in coupling with a sterically hindered 2‑aminopyridine derivative to construct a pyridyl‑thiazole amide, a structural analogue of the succinate dehydrogenase inhibitor framework. The amidation is performed by slow addition of the amine (0.95 eq.) in toluene containing triethylamine (1.5 eq.) while maintaining 10–15 °C. After aqueous washes (5% NaHCO₃, then water) and solvent swap to isopropyl alcohol, the target amide crystallizes with 88% yield and 99.5% purity by HPLC. Residual thionyl chloride‑derived impurities are controlled to <50 ppm by headspace GC conforming to EPA Method 8260D. The finished agrochemical intermediate is shipped against FAO specifications requiring a 5‑batch impurity profile and a 2‑year stability protocol at 25 °C/60% RH. Terminal application is as a late‑stage intermediate in a foliar fungicide candidate currently in field trials, where the 2‑chloro moiety acts as a metabolic soft spot tuned for plant systemic movement.

A Stable Acyl Donor for Dipeptidyl Peptidase-4 Inhibitor Scaffolds

While the methyl ester can be hydrolysed, it functions with greater atom economy as a direct acyl donor in trimethylaluminium‑mediated aminolysis. In a procedure validated at pilot scale, a 2 M solution of trimethylaluminium in toluene (2.0 eq.) is added to a suspension of an amino acid proline derivative (1.0 eq.) in anhydrous toluene (15 L/kg of amine) at 0 °C. The mixture is warmed to 25 °C over 30 min to form the aluminium amide, after which neat 2‑chloro‑4‑thiazolecarboxylic acid methyl ester (1.0 eq.) is added in one portion. The reactor is heated to 75 °C and held for 8 h. Conversion is monitored by TLC (silica, 40% EtOAc in hexane; R_f product ~0.45). The reaction is quenched by slow transfer into 20% aqueous Rochelle’s salt at <10 °C, and the aluminum‑chelate emulsion is broken by stirring for 12 h. The organic phase is separated, dried over sodium sulfate, and concentrated. Flash chromatography (gradient elution) gives the thiazole‑4‑carboxamide in 82–90% yield with >98% purity. The entire sequence complies with the principles of ICH Q8 (R2) quality‑by‑design: a three‑factor, two‑level DoE was employed to optimise stoichiometry, temperature, and addition order, and the design space was verified by a 12‑run confirmatory block. Residual aluminium in the isolated product is controlled below 5 ppm by IPC‑OES to meet ICH Q3D Option 1. The resulting 2‑chlorothiazole‑4‑carboxamide undergoes a copper‑catalysed cyanation to replace the chlorine with a nitrile group, furnishing a known DPP‑4 inhibitor pharmacophore. Published industrial reports indicate that the methyl ester route avoids the racemisation problems associated with activation of the free acid, making it the preferred starting point for multikilogram campaigns.

Pre‑activation of 2‑chloro‑4‑thiazolecarboxylic acid methyl ester into its organozinc derivative unlocks a modular Negishi cross‑coupling platform. Zinc dust (1.5 eq., ≥99.5% purity, 325 mesh) is suspended in N,N‑dimethylacetamide and activated with iodine (0.02 eq.) at 70 °C for 15 min. After cooling to 55 °C, the chloroester (1.0 eq.) is added, and the mixture is stirred for 3 h to form the 2‑zinc chloride intermediate. An aliquot quenched into D₂O and analysed by ¹H NMR shows complete disappearance of the 2‑H signal at δ 7.02. The organozinc solution is then cannula‑filtered into a separate 30‑L reactor charged with a heteroaryl bromide (0.95 eq.), Pd(dba)₂ (2.0 mol %), and XPhos (4.0 mol %). The coupling proceeds at 55 °C over 5 h, reaching 94% conversion by calibrated HPLC area percent. Quenching with 2 N hydrochloric acid is followed by extraction into ethyl acetate, and the combined organic layers are washed with a 5% EDTA‑disodium solution (3×2 L) to remove zinc. Residual zinc content in the crude product falls from 1200 ppm to 85 ppm, which is further reduced to 12 ppm after crystallisation from cyclohexane. The elemental impurity profile is documented against the PDE values of ICH Q3D (oral permitted daily exposure for zinc is 13 mg/day), ensuring compliance for an API starting material. The resulting 2‑heteroaryl‑4‑thiazolecarboxylic acid methyl ester library encompasses >50 analogues prepared under the same protocol, with isolated yields spanning 71–93%. The subsequent hydrolysis of the methyl ester is accomplished with K₂CO₃ in methanol/water (3:1 v/v) at 40 °C within 2 h, giving the free acids used directly in peptide coupling without further purification. A comparative table of alternative coupling modes is provided below, based on aggregated process data from multiple patent filings and development reports.

When the organozinc species derived from the 2‑chloro ester is engaged under continuous‑flow conditions, localised heat accumulation at the mixing point is sharply reduced. A 1.5 mm ID PFA tubular reactor charged with a zinc‑packed column and fed with the methyl ester (0.2 M in DMA) at 1.5 mL/min achieves 98% conversion to the organozinc intermediate at a residence time of 4.2 min. The outflow is combined with a stream of aryl bromide and Pd(dba)₂/XPhos (0.6 mol %) pre‑heated to 60 °C in a subsequent 10 mL coil reactor. This telescoped sequence delivers the cross‑coupled product with an average yield of 87% and cuts the total process time from 8 h batch to 12 min. Genotoxic potential of residual zinc cations is mitigated by an in‑line extractive membrane separator using an 8% citric acid solution, after which the organic stream is concentrated in a wiped‑film evaporator. The resulting crude oil is directly hydrolysed in a third flow module with LiOH (2.0 eq.) in THF/water at 30 °C with 90 sec residence. The free acid is collected by continuous crystallisation in a mixed‑suspension, mixed‑product‑removal crystallizer operated at −5 °C, yielding particles with D₅₀ 120 µm that are filtered and dried. Process analytical technology monitoring, including an online UPLC system sampling every 45 seconds, ensures that no unreacted chloroester (LOD 0.05%) bypasses the hydrolysis module. This end‑to‑end flow design exemplifies how an otherwise batch‑limited chlorine‑bearing synthon is converted into a high‑value biaryl acid for peptide‑functionalised conjugate therapeutics.